Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-07
2009-11-17
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S397000, C530S399000
Reexamination Certificate
active
07618938
ABSTRACT:
A method for treating a cerebrovascular disease with erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) jointly by first identifying a subject in need of the treatment and then administering to the subject an effective combined amount of EPO and G-CSF. Also disclosed is a method for increasing in a subject expression of EPO with G-CSF.
REFERENCES:
patent: 7220407 (2007-05-01), Mehta et al.
patent: 2003/0153503 (2003-08-01), Klaus et al.
Ehrenreich et al. A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia. Transfusion and Apheresis Science vol. 31:39-44 (2004).
Shyu et al. Functional recovery of stroke rats induced by granulocyte colony-stimulating factor-stimulated stem cells. Circulation vol. 110:1847-1854 (Sep. 20, 2004).
Ren et al. Growth factor and treatment of stroke. Current Drug Targets-CNS & Neurological Disorders vol. 4:121-125 (2005).
Cerebrovascular Disease (Neurosurgerytoday.org; pp. 1-11; Dec. 2005). www.neurosurgerytoday.org/what/patient—e/cerebrovascular.asp.
Casadevall et al., “Health, Economic and Quality-of-Life Effects of Erythropoietin and Granulocyte Colony-Stimulating Factor for the Treatment of Myelodysplastic Syndromes: A Randomized, Controlled Trial,”Blood, 104:321-327 (2004).
Pierelli et al., “Erythropoietin Addition to Granulocyte Colony-Stimulating Facto Abrogates Life-Threatening Neutropenia and Increases Peripheral-Blood Progenitor-Cell Mobilization After Epirubicin, Paclitaxel, and Cisplatin Combination Chemotherapy: Results of a Randomized Comparison,”J. Clin. Oncol., 17:1288-1295 (1999).
Pierelli et al., “In Vitro and In Vivo Effects of Recombinant Human Erythropoietin Plus Recombinant Human G-CSF on Human Haemopoietic Progenitor Cells,”Bone Marrow Transplantation, 14:23-30 (1994).
Pierelli et al., “The Combination of Erythropoietin and Granulocyte Colony-Stimulating Factor Increases the Rate of Haemopoietic Recovery with Clinical Benefit after Peripheral Blood Progenitor Cell Transplantation,”British Journal of Haematology92:287-294 (1996).
Signore et al., “Erythropoietin Protects Against 6-hydroxydopamine-induced Dopaminergic Cell Death,”Journal of Neurochemistry, 96:428-443 (2006).
Villa et al., “Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage After Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives,”Journal of Cerebral Blood Flow&Metabolism, advance online publication, Jul. 12, 2006; doi:10.1038/sj.jcbfm.9600370.
Wei et al., “Cell Death Mechanism and Protective Effect of Erythropoietin after Focal Ischemia in the Whisker-Barrel Cortex of Neonatal Rats,”The Journal of Pharmacology and Experimental Therapeutics, 317(1):109-116 (2006).
Zhang et al., “Erythropoietin Protects CA1 Neurons Against Global Cerebral Ischemia in Rat: Potential Signaling Mechanisms,”Journal of Neuroscience Research83:1241-1251 (2006).
Li Hung
Shyu Woei-Cherng
Academia Sinica
Allen Marianne P
DeBerry Regina M
Occhiuti Rohlicek & Tsao LLP
LandOfFree
Treating cerebrovascular diseases with erythropoietin and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating cerebrovascular diseases with erythropoietin and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating cerebrovascular diseases with erythropoietin and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4082573